Compare drug alternatives
Stelara® Alternatives
Stelara®(ustekinumab) | ®() |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$5. Learn more. | |
Annual Cap | |
Assistance Expiration | |
End of each calendar year (subject to change or discontinuation without notice). Learn more. | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions are:
• Psoriasis (≥3%): nasopharyngitis, upper respiratory tract infection, headache,
and fatigue.
• Crohn’s Disease, induction (≥3%): vomiting.
• Crohn’s Disease, maintenance (≥3%): nasopharyngitis, injection site erythema,
vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract
infection, and sinusitis.
• Ulcerative colitis, induction (≥3%): nasopharyngitis
• Ulcerative colitis, maintenance (≥3%): nasopharyngitis, headache, abdominal
pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea . Learn more. | |
Mechanism of Actions (MoA) | |
Interleukin 12 Antagonist; Interleukin 23 Antagonist . Learn more. | |
Special Populations | |
Is STELARA® safe to use during pregnancy? Limited data on the use of STELARA® in pregnant women are insufficient to inform a drug-associated risk. Animal studies have not shown any adverse effects, but the background risk of major birth defects and miscarriage for the indicated population(s) is unknown. Pregnant women should only use STELARA® if the potential benefits outweigh the risks. Is it safe to use STELARA® while breastfeeding? There is no data on the presence of ustekinumab in human milk or the effects on milk production or the breastfed infant. Ustekinumab was present in the milk of lactating monkeys administered ustekinumab. Breastfeeding women should only use STELARA® if the potential benefits outweigh the risks. Can children use STELARA®? STELARA® is approved for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 to 17 years old, and psoriatic arthritis in pediatric patients 6 to 17 years old. Use in patients less than 6 years of age with psoriasis or psoriatic arthritis or in pediatric patients with Crohn’s disease or ulcerative colitis has not been established. Is STELARA® safe for geriatric patients? Although no overall differences in safety or efficacy were observed between older and younger patients, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients. Geriatric patients using STELARA® may have a higher frequency of serious infection, so caution should be used when treating them. | |